AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 22 min read$NBIX

Delaet Ingrid sold $354K of NBIX

Delaet Ingrid (Chief Regulatory Officer) sold 2,261 shares of NEUROCRINE BIOSCIENCES INC (NBIX) at $156.71 ($0.35M total) on 2026-05-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Delaet Ingrid
Published Jun 2, 2026, 10:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 2, 2026, 10:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NBIX
Neutral
medium confidence
Mentioned
$NBIX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NBIXNeutralLow
01

Why it matters

This adds a datapoint on insider behavior but does not introduce new company-specific fundamentals (no trial, approval, guidance, or legal/regulatory event mentioned).

02

Market read

Traders may note the insider sale for sentiment, but 10b5-1 typically limits tradable informational edge.

03

What to watch

Insider sale size vs. total holdings is not provided beyond post-transaction shares; without context on prior sales cadence, the signal is weak.

Relevance 6/10Novelty 3/10Timing: Filed June 2; sale executed May 29 (10b5-1 plan).

Background

SEC Form 4 disclosure of an officer’s transaction in the issuer’s common stock.

Company-level read

Ticker impact

$NBIXNeutralMedium confidence
Context

Neurocrine Biosciences insider (Chief Regulatory Officer) sold $354.3K of NBIX shares via an open-market sale under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small unless paired with other catalysts.

Evidence & confidence

Form 4 provides a transaction datapoint without new operational/clinical/regulatory information; 10b5-1 indicates planned execution rather than new negative information.

Market effects

Sector

Minimal; this is company-specific insider activity with no stated sector-wide catalyst.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is 10b5-1, it may reflect routine liquidity planning rather than a view on fundamentals.

Key entities

  • issuer
    Neurocrine Biosciences, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Delaet Ingrid

    Chief Regulatory Officer who sold NBIX shares under a Rule 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NBIX insider trading history →

Related articles

SEP 18
$NBIXMedAI 8/10

Neurocrine’s (NBIX) Data Deluge Reshapes A Familiar Growth Story

Neurocrine Biosciences (NBIX) reported positive Phase 4 study results for INGREZZA, showing significant patient improvement in tardive dyskinesia. The company also reported Q2 revenue growth of 39% to $959M, with INGREZZA sales up 15%. Neurocrine acquired Soleno Therapeutics, reducing cash reserves but expanding its drug portfolio. The stock trades at a forward P/E of 14.88.

insidermonkey.com2 min
AUG 12
$NBIXMed

Why is Neurocrine Biosciences stock sliding today?

Neurocrine Biosciences (NBIX) shares fell about 3.1% to $156.94 after three Prader-Willi patient groups issued a joint statement citing post-marketing safety data for Neurocrine’s Vykat XR, including seven patient deaths and 100+ serious adverse events reported to the FDA. The groups did not claim causality. CEO Kyle Gano disputed a link. Investors also weighed INGREZZA drug-pricing concerns; Q2 2026 revenue was reported above $950M.

investing.com6 min